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Abstract: Background: Metformin is commonly used to treat gestational diabetes mellitus. This study
investigated the effect of maternal metformin intervention during obese glucose-intolerant pregnancy
on the gonadal white adipose tissue (WAT) of 8-week-old male and female mouse offspring. Methods:
C57BL/6J female mice were provided with a control (Con) or obesogenic diet (Ob) to induce pre-
conception obesity. Half the obese dams were treated orally with 300 mg/kg/d of metformin
(Ob-Met) during pregnancy. Gonadal WAT depots from 8-week-old offspring were investigated for
adipocyte size, macrophage infiltration and mRNA expression of pro-inflammatory genes using
RT-PCR. Results: Gestational metformin attenuated the adiposity in obese dams and increased the
gestation length without correcting the offspring in utero growth restriction and catch-up growth
caused by maternal obesity. Despite similar body weight, the Ob and Ob-Met offspring of both sexes
showed adipocyte hypertrophy in young adulthood. Male Ob-Met offspring had increased WAT
depot weight (p < 0.05), exaggerated adipocyte hyperplasia (p < 0.05 vs. Con and Ob offspring),
increased macrophage infiltration measured via histology (p < 0.05) and the mRNA expression of
F4/80 (p < 0.05). These changes were not observed in female Ob-Met offspring. Conclusions: Maternal
metformin intervention during obese pregnancy causes excessive adiposity, adipocyte hyperplasia
and WAT inflammation in male offspring, highlighting sex-specific effects of prenatal metformin
exposure on offspring WAT.
Keywords: gestational diabetes; foetal programming; metformin; maternal obesity; white adipose
tissue; sex differences
1. Introduction
The prevalence of obesity is rising at sufficiently rapid rates such that over 50% of
women of child-bearing age in the UK are currently overweight or obese [1]. Obesity
is not only associated with adverse metabolic and cardiovascular events in the adult
female [2], but, when present during pregnancy, it also has long-term ‘programming effects’
on exposed offspring that increase their risk of obesity, insulin resistance, type 2 diabetes
and the metabolic syndrome [3].
Women with obesity are four times more likely to develop gestational diabetes melli-
tus (GDM) during pregnancy [4]. Metformin is the first-line pharmacological treatment
for GDM in many countries, including the UK, when lifestyle interventions are ineffective,
and its use has been increasing worldwide [5,6]. In pregnancy, metformin improves glu-
cose tolerance in women with GDM, and metformin treatment is associated with a lower
Int. J. Mol. Sci. 2021, 22, 8104. https://doi.org/10.3390/ijms22158104 https://www.mdpi.com/journal/ijms
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by Apollo
Int. J. Mol. Sci. 2021, 22, 8104 2 of 14
gestational weight gain compared to insulin or placebo in GDM or obese glucose-tolerant
women, respectively [7,8]. Its oral administration, lack of requirement for refrigerated
storage, and cost-effectiveness also make it more appropriate than insulin for use in low-
resource settings. Therefore, it is plausible that metformin use in pregnancy might offer
a suitable intervention to mitigate or negate the adverse effects of an obese diabetic in-
trauterine environment on offspring health globally. However, metformin readily crosses
the placenta [9], and offspring follow-up in human randomised controlled trials investigat-
ing maternal metformin treatment remains sparse, with few studies reporting offspring
outcomes beyond infancy [10–15]. However, the fact that several studies have reported
an increased adiposity in children exposed to maternal metformin treatment in pregnancy
warrants further investigation into the long-term effects [10,12,13]. Animal studies are
therefore essential to determine the direct and indirect effects of maternal and in utero
metformin exposure on offspring adiposity, adipose tissue biology and metabolic health.
Moreover, animal studies allow the investigation of potentially sexually dimorphic effects,
whereas human follow-up studies are often insufficiently powered to perform this analysis.
In our well-established mouse model of maternal diet-induced obesity [16], dams are
fed an obesogenic diet high in both fat and sugar before mating and are consequently obese,
hyperleptinaemic and hyperinsulinaemic at conception and develop glucose intolerance
in pregnancy [16–18]. It was previously found that male offspring of obese dams develop
obesity from 12 weeks of age, while adipocyte hypertrophy is present from as early as
8 weeks of age [16,19,20]. We and others have shown that the programming effects of
maternal obesity on male rodent offspring adiposity and adipose tissue function can be
ameliorated by maternal exercise intervention [17,21,22]. Although the effects of early
life exposure to metformin on offspring body composition have been reported in several
rodent models [23–29], the effects of clinically relevant maternal metformin intervention
exclusively during obese glucose-intolerant pregnancy (and not lactation) on offspring WAT
have not been studied. Furthermore, growing evidence indicates that programming effects
can be sexually dimorphic, with males and females responding differently or showing a
different time course of response to a suboptimal in utero environment [30], highlighting
the importance of including both male and female offspring in this study.
This study therefore aimed to investigate the effect of maternal metformin intervention
during obese glucose-intolerant pregnancy on 8-week-old offspring gonadal WAT using
a mouse model of diet-induced obesity. Importantly, as it has emerged that there can
be sex-specific effects of in utero exposures, this study included both male and female
offspring. We report that maternal obesity caused gonadal adipocyte hypertrophy, which
was not corrected by the metformin intervention. Instead, the metformin intervention
increased adipocyte hyperplasia, macrophage infiltration and gonadal WAT inflammation
in male but not female offspring.
2. Results
2.1. Metformin Attenuates Fat Mass in Diet-Induced Obese Dams
Ob and Ob-Met dams were fed an obesogenic diet prior to mating, and hence had
a higher body weight and fat mass than Con dams did in late gestation (Table 1). The
metformin intervention decreased maternal body weight and fat mass (but not lean mass)
at E15.5. Maternal obesity caused a reduction in litter size (from 7 to 6 pups per litter,
Table 1). This reduction was not prevented by maternal metformin treatment (Table 1).
Maternal obesity also led to a decreased pup weight on postnatal day 2 (PN2) (from
1.9 to 1.6 g per pup, Table 1). This growth restriction was not prevented by maternal
metformin administration (Table 1), despite the increased gestation length observed in
metformin-treated obese pregnancies (Table 1).
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Table 1. Dam body composition and pregnancy outcomes. * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001 vs. Con, # p < 0.05, ## p < 0.01, ### p < 0.001 vs. Ob using one-way ANOVA with
Tukey’s multiple comparison test, Kruskal–Wallis test for nonparametric data (gestation length and
litter size) or ANOVA performed on log-transformed data (PN2 weight). E15.5 = embryonic day 15.5.
ns = not significant. PN2 = postnatal day 2.
Con Ob Ob-Met p-Value
Dams at E15.5 n = 15 n = 13 n = 6–7
Body weight (g) 36.0 ± 0.7 49.0 ± 0.8 *** 44.9 ± 1.2 ***,# <0.0001
Lean mass (g) 23.9 ± 0.7 24.7 ± 0.6 23.9 ± 0.6 ns
Fat mass (g) 4.5 ± 0.3 15.6 ± 0.6 *** 12.4± 0.6 ***,### <0.0001
Fat mass (%) 12.5 ± 0.7 31.7 ± 0.9 *** 27.6 ± 0.9 ***,### <0.0001
Pregnancy outcome n = 24–31 n = 30–33 n = 20–26
Gestation length (d) 20 [19, 20] 20 [21, 22] 21 [20.3–21] ***,## <0.0001
Litter size (no pups) 7.0 [6.0–9.0] 6.0 [5.0–7.0] ** 6.0 [5.0–7.0] * 0.0015
PN2 weight (g/pup) 1.9 ± 0.04 1.6 ± 0.04 **** 1.7 ± 0.04 *** <0.0001
2.2. Maternal Metformin Treatment Induces Adiposity in Male but Not Female Offspring
Pups born to Ob dams were lighter at PN2 but displayed catch-up growth leading to
higher pup weights than the controls by PN14, and this difference remained at PN21. This
was not corrected by the metformin intervention (Figure 1A). After weaning, there were no
differences in body weight between any of the three groups up to 8 weeks of age (Figure
1B). However, the weights of the gonadal, intraperitoneal, and subcutaneous WAT depots at
8 weeks of age were significantly increased in male Ob-Met offspring (Figure 1C). This was
not observed in female Ob-Met offspring (Figure 1D).
2.3. Metabolic Health Is Not Affected by Maternal Obesity or Metformin Exposure
Serum insulin did not significantly differ between groups in either male (Con 50 ± 6,
Ob 67 ± 6, Ob-Met 73 ± 10 pmol/L, p = 0.1697, one-way ANOVA) or female offspring
(Con 77 ± 15, Ob 67 ± 7, Ob-Met 52 ± 4 pmol/L, p = 0.1417, one-way ANOVA). Similarly,
there was no difference in glucose tolerance, as measured by the intraperitoneal glucose
tolerance test in male (Con 1340 ± 51, Ob 1448 ± 57, Ob-Met 1343 ± 67 AUC, p = 0.3463,
one-way ANOVA) or female offspring (Con 1209 [1183–1321], Ob 1274 [1106–1379], Ob-Met
1235 [1160–1416] AUC, p = 0.9920, Kruskal–Wallis test).
2.4. Gonadal WAT Cellularity Is Altered by Maternal Obesity and Metformin Intervention
Male and female Ob and Ob-Met offspring showed gonadal adipocyte hypertrophy
indicated by the rightward shift in the adipocyte size distribution compared to Con off-
spring (Figure 2A,C, p < 0.0001 for the interaction between the maternal environment and
adipocyte size, two-way ANOVA). This was particularly apparent in the larger adipocyte
range, although male Ob-Met offspring also showed an increase in small adipocytes
(Figure 2A, left). Maternal obesity increased the estimated adipocyte number in male
but not female offspring, and this was exaggerated by exposure to maternal metformin
treatment with male offspring of obese metformin-treated dams having significantly more
adipocytes than male offspring of obese (and control) dams did (Figure 2B).
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Figure 1. Offspring growth and adiposity in 8-week-old offspring. (A) Growth trajectory of neonatal offspring (n = 26–33 
independent litters per group, sexes combined). **** p < 0.0001 vs. Con vs. Ob, # p < 0.05, #### p < 0.001 Con vs. Ob-Met using 
Figure 1. Offspring growth and adiposity in 8-week-old offspring. (A) Growth trajectory of neonatal offspring (n = 26–33
independent litters per group, sexes combined). **** p < 0.0001 vs. Con vs. Ob, # p < 0.05, #### p < 0.001 Con vs. Ob-Met
using two-way ANOVA with Tukey’s multiple comparison test. (B) Post-weaning body weight trajectory in male and
female offspring until 8 weeks of age (n = 10–14 independent litters per group). (C,D) Weight of white adipose tissue (WAT)
depots collected at 8 weeks of age relative to offspring body weight (n = 8–10 independent litters per group). Outliers were
excluded from (C) iWAT and sWAT; female Ob (Grubb’s method, outlier excluded values 1.03% and 1.45%, respectively).
* p < 0.05 using one-way ANOVA with Tukey’s multiple comparison test. gWAT = gonadal depot, iWAT = intraperitoneal
depot, rWAT = retroperitoneal depot, sWAT = subcutaneous depot. Con (circles, solid line) = offspring of control-fed
dams, Ob (squares, dashed line) = offspring of obese dams, Ob-Met (triangles, dotted and dashed line) = offspring of obese
metformin-treated dams. Panels (B–D): closed symbols denote male offspring; open symbols denote female offspring.
2.5. Maternal Metformin Introduces Gonadal WAT Inflammation in Male Offspring
Male Ob-Met offspring showed increased CLS in adipose tissue, indicating a pro-
inflammatory signature of the gonadal WAT (Figure 3A,B). This was not seen in female
offspring. Accordingly, the expression of the macrophage marker F4/80 was specifi-
cally increased in male Ob-Met offspring compared to both Con and Ob offspring WAT
(Figure 3C). Cd11c (a pro-inflammatory M1-type macrophage marker) expression was not
affected by maternal obesity or metformin treatment. Overall, F4/80 and Cd11c expressions
were lower in female compared to male WAT.




Figure 2. Cellularity of 8-week-old gonadal adipocytes. (A) Adipocyte size distribution in male (left) and female (right) 8-
week-old offspring. (B) Estimated adipocyte number in the collected gonadal white adipose tissue (WAT) depot. * p < 0.05, 
**** p < 0.0001 using one-way ANOVA with Tukey’s multiple comparison test. (C) Representative images of H&E-stained 
sections used for cell size analysis. Con (circles, solid line) = offspring of control-fed dams, Ob (squares, dashed line) = 
offspring of obese dams, Ob-Met (triangles, dotted and dashed line) = offspring of obese metformin-treated dams. Closed 
symbols denote male offspring; open symbols denote female offspring. n = 9–14 independent litters per group. Outliers 
were excluded from (B); male Con (Grubb’s method, outlier excluded value 6.28 × 106). 
2.5. Maternal Metformin Introduces Gonadal WAT Inflammation in Male Offspring 
Male Ob-Met offspring showed increased CLS in adipose tissue, indicating a pro-
inflammatory signature of the gonadal WAT (Figures 3A,B). This was not seen in female 
offspring. Accordingly, the expression of the macrophage marker F4/80 was specifically 
increased in male Ob-Met offspring compared to both Con and Ob offspring WAT (Figure 
Figure 2. Cellularity of 8-week-old gonadal adipocytes. (A) Adipocyte size distribution in male (left) and female (right)
8-week-old offspring. (B) Estimated adipocyte number in the collected gonadal white adipose tissue (WAT) depot.
* p < 0.05, **** p < 0.0001 using one-way ANOVA with Tukey’s multiple comparison test. (C) Representative im-
ages of H&E-stained sections used for cell size analysis. Con (circles, solid line) = offspring of control-fed dams,
Ob (squares, dashed line) = offspring of obese dams, Ob-Met (triangles, dotted and dashed line) = offspring of obese
metformin-treated dams. Closed symbols denote male offspring; open symbols denote female offspring. n = 9–14 indepen-
dent litters per group. Outliers were excl ded from (B); male Con (Grubb’s method, outlier excluded value 6.28 × 106).
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Figure 3. Inflammation in gonadal white adipose tissue. (A) Presence of crown-like structures (CLS) in gonadal white
adipose tissue (WAT) of 8-week-old mal (left) and female (right) offspring, expressed as percentage area of the WAT
tissue and as the number of CLS divided by the number of adipocytes in the section (n = 10–15 independent litters per
group). * p < 0.05 using one-way ANOVA with Tukey’s multiple comparison test. (B) Representative images of H&E-stained
sections used for CLS analysis. (C) mRNA expression of macrophage markers in gonadal WAT relative to the expression
of housekeeper gene Ppia and the male Con group (n = 7–10 independent litters per group). * p < 0.05, *** p < 0.001,
**** p < 0.0001 for the main effect of sex (S), interaction between sex and the maternal environment (X) or Tukey’s multiple
comparison using two-way ANOVA. Outliers were excluded from (A) CLS density; female Con (Grubb’s method, outlier
excluded value 0.46%), and (A) %adipocytes with CLS; male Con (Grubb’s method, outlier excluded value 1.19%). From
(C) F4/80, two data points were excluded due to pipetting errors (male Con and female Ob). From (C) Cd11c, one data point
was excluded due to pipetting errors (female Con).
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3. Discussion
This study showed that maternal metformin treatment during obese pregnancy de-
creased maternal fat mass and body weight in late gestation, but failed to correct the
decreased litter size, growth restriction with catch-up growth phenotype and adipocyte
hypertrophy in offspring exposed to maternal obesity. Moreover, in 8-week-old male
offspring, maternal metformin intervention exaggerated the adiposity phenotype char-
acterised by excessive adipocyte hyperplasia, macrophage infiltration and expression of
pro-inflammatory genes. This was not observed in female offspring.
Metformin is known to reduce body weight in nonpregnant type 2 diabetic pa-
tients [31], and an effect of metformin to lower gestational weight gain is a common
observation in human trials in GDM, polycystic ovary syndrome (PCOS) and obese
women [8,32,33]. Our findings of lower body weight and fat mass, consistent with a
protective effect of metformin on diet-induced obesity in late gestation, are therefore in
accordance with human data, supporting the validity of our model in assessing other
effects of metformin treatment during pregnancy, including the potential long-term effects
of metformin exposure in utero on offspring health. As metformin can cross the placenta
and enter the foetal circulation, attaining similar circulating concentrations to those in
the mother, the need for long-term follow-up studies has been highlighted [34]. As these
studies are both challenging to carry out and take many years in humans, animal models
are important to address this question.
Maternal obesity during pregnancy is associated with an increased risk of both small
and large for gestational age babies [35]. Consistent with previous studies in the model
[16,36,37], we observed growth restriction followed by catch-up growth in offspring ex-
posed to maternal obesity. The combination of low birth weight and accelerated postnatal
growth is associated with long-term adverse effects on offspring cardiometabolic health
in human studies [38–41] and animal models [42,43]. The metformin intervention did
not correct (or worsen) this pattern of early growth. However, our study is the first to
report that metformin intervention in the obese mouse dam increased gestation time by
one day. Therefore, the equivalent growth restriction observed in both Ob and Ob-Met
pups, despite the delay in parturition, might suggest that metformin-exposed foetuses
would be further growth-restricted compared to nonexposed foetuses if assessed on the
same gestational day.
The mechanism by which metformin causes adiposity in male offspring is unclear.
Metformin is known to activate AMPK, causing inhibition of mTOR, decreased cell pro-
liferation, suppression of protein synthesis and cell cycle arrest [34]. Such a mechanism
acting on foetal tissue could explain the relative growth restriction observed, which is
masked in terms of birthweight due to the delay in parturition. Providing metformin in
obese pregnancy but not lactation may thus reflect a model of growth restriction (due
to metformin) with catch-up growth (following metformin removal at birth) similar to
studies in which recuperated offspring displayed rapid post-natal growth following in
utero low-protein exposure [42]. This was also proposed by Salomäki et al. who drew a
comparison between their model of gestational metformin treatment to chow-fed dams and
developmental programming by maternal undernutrition [26]. Indeed, when looking at
studies investigating male offspring adiposity in nontransgenic rodent models (including
the current study), metformin was only detrimental to offspring body composition in
situations where this cellular ‘starvation’ was followed by restored or increased energy
balance in lactation, whereas continued metformin treatment or switching to a healthy
diet postnatally was associated with protective effects [23,25,26]. Whether this relates to
direct effects of metformin signalling on foetal development or indirectly through effects
on maternal metabolism is unclear. Combined with the increased gestation length in this
study and the human data summarised above, this suggests that metformin may adversely
affect intrauterine development, particularly for male offspring.
At 8 weeks of age, the body weight and weight of both visceral (epididymal, intraperi-
toneal and retroperitoneal) and subcutaneous WAT depots did not differ between Con
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and Ob offspring despite evidence of gonadal adipocyte hypertrophy in both sexes, in
accordance with previous reports in male offspring [19]. In contrast, maternal metformin
treatment introduced male-specific increased adiposity, while female offspring were un-
affected. The increased adiposity in male Ob-Met compared to Ob offspring was likely
driven by hyperplasia as adipocyte size was unaffected by the metformin intervention.
This early life hypercellularity may predispose offspring to becoming obese later in life
by increasing the lifelong lipid-storage capacity of WAT. In addition to being increased in
mass, the hypertrophic gonadal WAT of males exposed to metformin in utero displayed
increased CLS density and mRNA expression of the macrophage marker F4/80, indicative
of enhanced macrophage infiltration. This was not seen in Ob offspring, indicating a
more progressive WAT dysfunction phenotype in Ob-Met offspring despite similar lev-
els of hypertrophy, a known stimulus for macrophage invasion [44]. The percentage of
adipocytes surrounded by CLS, a marker of adipocyte death [44,45], was also increased
in Ob-Met compared to Ob offspring. This suggests that in utero metformin exposure
increased the adipocyte death rate in male Ob-Met WAT, leading to the recruitment of
immune cells, phagocytosis of necrotic adipocytes and production of pro-inflammatory
mediators. The increased prevalence of CLS in Ob-Met gonadal WAT may be related to
the increased hyperplasia as ‘obesity-induced adipocyte death’ has been suggested as the
limiting factor to adipocyte hypertrophy and may underlie the switch from hypertrophic
to hyperplastic adiposity [44]. Inflammation is a major contributor to adipose tissue insulin
resistance. However, no adverse metabolic phenotype was observed in Ob-Met offspring
at this age. This is not surprising, as WAT inflammation is known to precede systemic
hyperinsulinaemia [46], suggesting that metabolic alterations may develop at a later age.
Female offspring were relatively protected against programmed adiposity in this study
with no effects of either maternal obesity or metformin on weights of the visceral WAT
depots. Female 8-week-old offspring also showed a lower expression of pro-inflammatory
genes compared to males, consistent with reports that basal cytokine and chemokine
expressions are higher in male compared to female WAT [47]. In contrast to males, there
was no maternal environment effect on CLS formation in female offspring, indicating a
sexually dimorphic susceptibility to WAT inflammation in a programming context. This is
in accordance with previous reports showing that maternal high-fat feeding in pregnancy
leads to macrophage invasion in chow-fed male offspring, while female offspring required
a postnatal high-fat diet to show upregulated pro-inflammatory gene expression. Even
then, the phenotype was milder than that in high-fat-diet-fed males [48]. The mechanisms
underlying the sex differences in our study are unknown, but anti-inflammatory actions of
oestrogen in female offspring are suggested as one explanation [48]. Sexual dimorphism in
a developmental programming context is becoming increasingly recognised, with male
offspring often more vulnerable to suboptimal in utero exposures than female offspring are,
and subsequently displaying earlier and/or more severe phenotypes in adulthood. This
may be related to sexually dimorphic patterns and the timing of development, different
hormonal intrauterine and postnatal environments and the observation that males grow
faster in utero than females do [49,50].
The murine data we report here are broadly consistent with the limited data available
in humans. We showed in a recent meta-analysis of human randomised controlled trials
that metformin treatment in gestational diabetic pregnancies is associated with decreased
birth weight compared to those treated with insulin [51]. Although usually interpreted as
beneficial (prevention of macrosomia), this may reflect the relative growth restriction that
is masked by the obesogenic glucose-intolerant environment. Accordingly, we showed
that the decreased birth weight observed in metformin-treated human GDM pregnancies
is followed by increased postnatal growth, leading to heavier infants compared to insulin-
treated GDM [51]. The longest human follow-up of metformin-treated GDM pregnancies to
date is from the MiG trial in Australasia. In 2011, this trial reported an increased adiposity
in two-year-old metformin-exposed offspring. As no detectable change was seen in visceral
fat mass at this age, the authors proposed that this might reflect expansion of the more
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metabolically beneficial subcutaneous depot [52]. Our current animal study, however, does
not support depot-specificity but instead shows a global adiposity phenotype involving
both subcutaneous and visceral depots, the latter of which was also shown by another
mouse study [26]. Therefore, it is interesting to note that further follow-up from the
MiG trial has since shown that adiposity in 9-year-old offspring was indeed globally
increased [10]. Furthermore, our meta-analysis of GDM intervention trials also confirmed
that compared to insulin, the lower birth weight and accelerated postnatal growth in
metformin-exposed babies lead to childhood adiposity [51], consistent with the current
mouse study.
Similar to findings in a GDM context, a placebo-controlled trial in PCOS women
showed excessive postnatal growth in metformin-exposed offspring with body weight and
BMI diverging from the placebo arm from 6 months of age [12]. Moreover, further follow-
up of offspring born to metformin-treated PCOS women up to 10 years of age showed
increased overweight and obesity [12,13], with an increased proportion of metabolically
abnormal obese children in the metformin arm. In contrast, trials in obese glucose-tolerant
women failed to show a relationship between metformin exposure and offspring adiposity
at least up to 4 years of age [8,14,53], highlighting the importance of the longer-term
follow-up of metformin-exposed offspring.
In addition to the different clinical indications, it is important to note that the timing
of metformin administration differs between women treated for GDM (in the second or
third trimester) and those with PCOS or type 2 diabetes (before or at conception) or studies
in nondiabetic obese women (end of the first trimester). However, the common outcome
of increased offspring adiposity in the context of PCOS and GDM suggests that exposure
during the last trimester is critical in relation to effects on adiposity. Unfortunately, most
human studies are not sufficiently powered to analyse potential sexual dimorphism in
offspring outcomes. The paucity of long-term offspring follow-up in humans means that
more evidence is required to determine potential critical time windows of exposure, sexual
dimorphism in foetal responses, as well as the interaction with maternal metabolic status.
In conclusion, maternal metformin treatment during obese pregnancy decreased
maternal fat mass in late gestation, providing a less obese intrauterine environment for de-
veloping foetuses, and consistent with beneficial effects on maternal physiology. However,
maternal metformin treatment did not prevent foetal growth restriction, despite an increase
in gestation length, or the postnatal catch-up growth phenotype in offspring of obese dams.
These findings suggest that beneficial effects in maternal physiology do not necessarily
translate to improved physiology in the offspring. Furthermore, we observed sex-specific
effects of maternal metformin on offspring adiposity, with exposed males demonstrating
increased adiposity and adipose tissue inflammation that were not observed in the fe-
males. These findings highlight the presence of sexually dimorphic responses to in utero
exposures and the need to consider immediate, as well as postnatal, effects of treatments
during pregnancy on mother and child. Given the importance of ageing in exaggerating
programmed phenotypes and in the development of metabolic disease pathology, it is
imperative that these offspring are followed up to determine whether these alterations in
adipose biology in young adult life become pathological in later life.
4. Materials and Methods
4.1. Animal Model
All mouse work was performed according to the UK Home Office Animals (Scientific
Procedures) Act 1986 Amendment Regulations 2012 and the University of Cambridge
Animal and Welfare Ethical Review Board, approved under project licence P5FDF0206,
23 March 2017. As previously described [17], female C57BL/6J mice were randomly
assigned to either a standard laboratory chow (RM1, 7% sugars, 3% fat) or a high-fat
diet (10% sugars, 20% fat) supplemented with sweetened condensed milk (55% sugar,
8% fat) and vitamin and mineral pre-mix (AIN-93G-MX, Special Diets Services, Witham,
UK) from weaning. After 6 weeks, they were mated for a primary pregnancy to ensure
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breeding effectiveness. Obese dams were mated for the experimental pregnancy when
they reached a critical threshold of 12 g absolute fat mass, as measured by noninvasive
time-domain nuclear magnetic resonance (TD-NMR, Bruker Minispec LF series, Bruker
Optik GmbG, Essex, Germany), whereas control dams remained below 5 g absolute fat
mass at mating. Dams were fed their respective diets ad libitum throughout pregnancy
and lactation. Half of obese dams were treated orally with 300 mg/kg/d of metformin-
hydrochloride supplemented in the condensed milk from one week pre-mating until
embryonic day 19 (E18.5). This clinically relevant dose has previously been used in murine
models and equates to a dose similar to those provided to pregnant women [26]. The body
composition of dams in all three groups was measured by TD-NMR on E15.5. Litter size
was standardised to six pups per litter on PN2. Male and female offspring were weaned
onto RM1 at PN21 and housed in littermate pairs of the same sex until culling at 8 weeks of
age using rising CO2 concentration. Excised adipose tissues from fed animals or following
a 16 h fast were formalin-fixed or snap-frozen on dry ice, respectively.
4.2. Gene Expression
Gonadal adipose tissue was lysed on ice in QIAzol Lysis Reagent (Qiagen, Hilden,
Germany) using the TissueRuptor II (Qiagen). RNA was extracted using the miRNeasy
MiniKit (Qiagen) with DNase digestion (RNase-Free DNase Set, Qiagen) according to
the manufacturer’s protocols. RNA concentration was determined using a NanoDrop
1000 Spectrophotometer (ThermoScientific, UK) and RNA quality was assessed using gel
electrophoresis. cDNA was generated using the HiCapacity RT kit (Applied Biosystems,
USA) with addition of the RNAse inhibitor (Applied Biosystems) using the Veriti™ 96-Well
Thermal Cycler (Applied Biosystems). Real-time quantitative PCR was performed in dupli-
cate using a SYBR™ Select Master Mix (Applied Biosystems) and the QuantStudio™ 7 Flex
Real-Time PCR System (Applied Biosystems). Data were normalised using the comparative
CT method against the expression of Ppia (which was unaffected by experimental group or
sex) relative to the expression in the male control group. Primer sequences are shown in
Table 2.
Table 2. Primer sequences for RT-PCR.





Formalin-fixed gonadal adipose tissue was processed, embedded and sectioned, and
3 µm sections were stained with haematoxylin and eosin (H&E). Whole sections were
scanned using the Axioscan digital slide scanner (Zeiss, Germany). Images were analysed
using HALO analysis software (Indica labs, USA) using DenseNet AI Plugin classifiers
(‘crown-like structures’ or CLS analysis) and the Vacuole Quantification tool (adipocyte
cell size) adapted to the H&E-stained WAT sections. The estimated adipocyte number was
calculated based on methods previously described [28] by dividing the total volume of
gonadal WAT (estimated from the tissue weight and density of rodent visceral WAT) by
the mean adipocyte volume derived from the cross-sectional area measured by HALO.
The percentage adipocytes surrounded by CLS, a marker of adipocyte death [44], was
calculated by normalising the number of CLS by the number of adipocytes per section.
4.4. Intraperitoneal Glucose Tolerance Test
Following an overnight fast, offspring were injected intraperitoneally with 1 g/kg of
glucose solution. Blood glucose was measured from the tail vein at baseline and 15, 30, 60
and 120 min post-injection (AlphaTRAK2, Zoetis, Parsippany-Troy Hills, NJ, USA). The
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area under the glucose excursion curve during the glucose tolerance test was computed
using the trapezoid rule in Prism 8.0 (GraphPad, La Jolla, CA, USA).
4.5. Serum Analysis
Terminal blood was collected following a 16 h fast by cardiac puncture. Serum was
collected after centrifugation at 3000× g and stored at −80 ◦C. Serum insulin was measured
using the Ultra-Sensitive Mouse Insulin ELISA Kit (Crystal Chem, Elk Grove Village, IL, USA).
4.6. Statistical Analysis
Data are presented as means ± SEM and were analysed using Prism 8.0 software
(GraphPad) using one-way ANOVA, two-way ANOVA or nonparametric alternatives
where appropriate. Outliers were determined by the Grubb’s method and excluded as
described in the figure legends. A p-value of p < 0.05 was considered statistically significant.
In all cases, n refers to the number of independent litters represented.
Author Contributions: Conceptualization, S.E.O.; formal analysis, J.M.S. and C.E.A.; funding acqui-
sition, S.E.O.; investigation, J.M.S., H.L.B., T.J.A. and D.S.F.-T.; methodology, H.L.B., D.S.F.-T. and
S.E.O.; project administration, J.M.S. and S.E.O.; supervision, S.E.O.; visualization, J.M.S. and S.E.O.;
writing—original draft, J.M.S.; writing—review and editing, H.L.B., D.S.F.-T. and C.E.A. All authors
have read and agreed to the published version of the manuscript.
Funding: This research was funded by the British Heart Foundation, grants RG/17/12/33167,
PG/13/46/30329 and studentship to JMS FS/16/53/32729, and the Medical Research Council, grants
MC_UU_00014/4 and MR/T016701/1.
Institutional Review Board Statement: All mouse work was performed according to the Home
Office Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012, after ethical review
by the University of Cambridge Animal and Welfare Ethical Review Board, approved under project
licence P5FDF0206, 23 March 2017.
Informed Consent Statement: Not applicable.
Data Availability Statement: As the manuscript does not include any omics data, the data presented
in this study are available on request from the corresponding author as appropriate (such as for use
in meta-analyses) following publication. The data are not publicly available.
Acknowledgments: The authors would like to acknowledge and thank Claire Custance for expert
technical assistance.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or
in the decision to publish the results.
References
1. Mullins, E.W.S.; Davies, S.C. Annual Report of the Chief Medical Officer, 2014, The Health of the 51%: Women; Department of Health:
London, UK, 2015.
2. Poirier, P.; Giles, T.D.; Bray, G.A.; Hong, Y.; Stern, J.S.; Pi-Sunyer, F.X.; Eckel, R.H. Obesity and cardiovascular disease: Pathophysi-
ology, evaluation, and effect of weight loss. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 968–976. [CrossRef] [PubMed]
3. Drake, A.J.; Reynolds, R.M. Impact of maternal obesity on offspring obesity and cardiometabolic disease risk. Reproduction 2010,
140, 387–398. [CrossRef] [PubMed]
4. Chu, S.Y.; Callaghan, W.M.; Kim, S.Y.; Schmid, C.H.; Lau, J.; England, L.J.; Dietz, P.M. Maternal obesity and risk of gestational
diabetes mellitus. Diabetes Care 2007, 30, 2070–2076. [CrossRef]
5. Cesta, C.E.; Cohen, J.M.; Pazzagli, L.; Bateman, B.T.; Bröms, G.; Einarsdóttir, K.; Furu, K.; Havard, A.; Heino, A.; Hernandez-Diaz,
S.; et al. Antidiabetic medication use during pregnancy: An international utilization study. BMJ Open Diabetes Res. Care 2019, 7,
e000759. [CrossRef] [PubMed]
6. National Institute for Health and Care Excellence. Diabetes in pregnancy: Management from preconception to the postnatal
period (NG3). 2015. Available online: https://www.nice.org.uk/guidance/NG3 (accessed on 1 July 2021).
Int. J. Mol. Sci. 2021, 22, 8104 12 of 14
7. Barrett, H.L.; Gatford, K.L.; Houda, C.M.; De Blasio, M.J.; McIntyre, H.D.; Callaway, L.K.; Nitert, M.D.; Coat, S.; Owens,
J.A.; Hague, W.M.; et al. Maternal and neonatal circulating markers of metabolic and cardiovascular risk in the metformin in
gestational diabetes (MiG) trial: Responses to maternal metformin versus insulin treatment. Diabetes Care 2013, 36, 529–536.
[CrossRef]
8. Syngelaki, A.; Nicolaides, K.H.; Balani, J.; Hyer, S.; Akolekar, R.; Kotecha, R.; Pastides, A.; Shehata, H. Metformin versus Placebo
in Obese Pregnant Women without Diabetes Mellitus. N. Engl. J. Med. 2016, 374, 434–443. [CrossRef] [PubMed]
9. Eyal, S.; Easterling, T.R.; Carr, D.; Umans, J.G.; Miodovnik, M.; Hankins, G.D.V.; Clark, S.M.; Risler, L.; Wang, J.; Kelly, E.J.; et al.
Pharmacokinetics of metformin during pregnancy. Drug Metab. Dispos. 2010, 38, 833–840. [CrossRef]
10. Rowan, J.A.; Rush, E.C.; Plank, L.D.; Lu, J.; Obolonkin, V.; Coat, S.; Hague, W.M. Metformin in gestational diabetes: The offspring
follow-up (MiG TOFU): Body composition and metabolic outcomes at 7–9 years of age. BMJ Open Diabetes Res. Care 2018, 6,
e000456. [CrossRef] [PubMed]
11. Rø, T.B.; Ludvigsen, H.V.; Carlsen, S.M.; Vanky, E. Growth, body composition and metabolic profile of 8-year-old children
exposed to metformin in utero. Scand. J. Clin. Lab. Investig. 2012, 72, 570. [CrossRef] [PubMed]
12. Hanem, L.G.E.; Salvesen, Ø.; Juliusson, P.B.; Carlsen, S.M.; Nossum, M.C.F.; Vaage, M.Ø.; Ødegård, R.; Vanky, E. Intrauterine
metformin exposure and offspring cardiometabolic risk factors (PedMet study): A 5–10 year follow-up of the PregMet randomised
controlled trial. Lancet Child Adolesc. Health 2019, 3, 166–174. [CrossRef]
13. Hanem, L.G.E.; Stridsklev, S.; Júlíusson, P.B.; Salvesen, Ø.; Roelants, M.; Carlsen, S.M.; Ødegård, R.; Vanky, E. Metformin Use in
PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. J. Clin. Endocrinol.
Metab. 2018, 103, 1612–1621. [CrossRef]
14. Panagiotopoulou, O.; Syngelaki, A.; Georgiopoulos, G.; Simpson, J.; Akolekar, R.; Shehata, H.; Nicolaides, K.; Charakida, M.
Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring. Am. J. Obstet. Gynecol. 2020,
223, 246.e1–246.e10. [CrossRef]
15. Tertti, K.; Toppari, J.; Virtanen, H.E.; Sadov, S.; Rönnemaa, T. Metformin treatment does not affect testicular size in offspring born
to mothers with gestational diabetes. Rev. Diabet. Stud. 2016, 13, 59–65. [CrossRef]
16. Samuelsson, A.M.; Matthews, P.A.; Argenton, M.; Christie, M.R.; McConnell, J.M.; Jansen, E.H.J.M.; Piersma, A.H.; Ozanne, S.E.;
Twinn, D.F.; Remacle, C.; et al. Diet-induced obesity in female mice leads to offspring hyperphagia, adiposity, hypertension, and
insulin resistance: A novel murine model of developmental programming. Hypertension 2008, 51, 383–392. [CrossRef]
17. Fernandez-Twinn, D.S.; Gascoin, G.; Musial, B.; Carr, S.; Duque-Guimaraes, D.; Blackmore, H.L.; Alfaradhi, M.Z.; Loche, E.;
Sferruzzi-Perri, A.N.; Fowden, A.L.; et al. Exercise rescues obese mothers’ insulin sensitivity, placental hypoxia and male offspring
insulin sensitivity. Sci. Rep. 2017, 7, 44650. [CrossRef] [PubMed]
18. Ingvorsen, C.; Thysen, A.H.; Fernandez-Twinn, D.; Nordby, P.; Nielsen, K.F.; Ozanne, S.E.; Brix, S.; Hellgren, L.I. Effects of
pregnancy on obesity-induced inflammation in a mouse model of fetal programming. Int. Obes. 2014, 38, 1–28. [CrossRef]
19. Alfaradhi, M.Z.; Kusinski, L.C.; Fernandez-Twinn, D.S.; Pantaleão, L.C.; Carr, S.K.; Ferland-McCollough, D.; Yeo, G.S.H.; Bushell,
M.; Ozanne, S.E. Maternal obesity in pregnancy developmentally programs adipose tissue inflammation in young, lean male
mice offspring. Endocrinology 2016, 157, 4246–4256. [CrossRef]
20. De Almeida Faria, J.; Duque-Guimarães, D.; Carpenter, A.A.M.; Loche, E.; Ozanne, S.E. A post-weaning obesogenic diet
exacerbates the detrimental effects of maternal obesity on offspring insulin signaling in adipose tissue. Sci. Rep. 2017, 7, 44949.
[CrossRef] [PubMed]
21. Vega, C.C.; Reyes-Castro, L.A.; Bautista, C.J.; Larrea, F.; Nathanielsz, P.W.; Zambrano, E. Exercise in obese female rats has
beneficial effects on maternal and male and female offspring metabolism. Int. J. Obes. 2015, 39, 712–719. [CrossRef] [PubMed]
22. Stanford, K.I.; Lee, M.-Y.Y.; Getchell, K.M.; So, K.; Hirshman, M.F.; Goodyear, L.J. Exercise Before and During Pregnancy
Prevents the Deleterious Effects of Maternal High-Fat Feeding on Metabolic Health of Male Offspring. Diabetes 2015, 64, 427–433.
[CrossRef] [PubMed]
23. Tong, J.F.; Yan, X.; Zhao, J.X.; Zhu, M.J.; Nathanielsz, P.W.; Du, M. Metformin mitigates the impaired development of skeletal
muscle in the offspring of obese mice. Nutr. Diabetes 2011, 1, e7. [CrossRef]
24. Salomäki-Myftari, H.; Vähätalo, L.H.; Ailanen, L.; Pietilä, S.; Laiho, A.; Hänninen, A.; Pursiheimo, J.-P.; Munukka, E.; Rintala,
A.; Savontaus, E.; et al. Neuropeptide Y overexpressing female and male mice show divergent metabolic but not gut microbial
responses to prenatal metformin exposure. PLoS ONE 2016, 11, e0163805. [CrossRef]
25. Salomäki, H.; Heinäniemi, M.; Vähätalo, L.H.; Ailanen, L.; Eerola, K.; Ruohonen, S.T.; Pesonen, U.; Koulu, M. Prenatal metformin
exposure in a maternal high fat diet mouse model alters the transcriptome and modifies the metabolic responses of the offspring.
PLoS ONE 2014, 9, e115778. [CrossRef]
26. Salomäki, H.; Vähätalo, L.H.; Laurila, K.; Jäppinen, N.T.; Penttinen, A.M.; Ailanen, L.; Ilyasizadeh, J.; Pesonen, U.; Koulu, M.
Prenatal Metformin Exposure in Mice Programs the Metabolic Phenotype of the Offspring during a High Fat Diet at Adulthood.
PLoS ONE 2013, 8, e56594. [CrossRef]
27. Gregg, B.E.; Botezatu, N.; Brill, J.D.; Hafner, H.; Vadrevu, S.; Satin, L.S.; Alejandro, E.U.; Bernal-Mizrachi, E. Gestational exposure
to metformin programs improved glucose tolerance and insulin secretion in adult male mouse offspring. Sci. Rep. 2018, 8, 5745.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 8104 13 of 14
28. Carlson, Z.; Hafner, H.; Mulcahy, M.; Bullock, K.; Zhu, A.; Bridges, D.; Bernal-Mizrachi, E.; Gregg, B. Lactational Metformin
Exposure Programs Offspring White Adipose Tissue Glucose Homeostasis and Resilience to Metabolic Stress in a Sex-Dependent
Manner. Am. J. Physiol. Endocrinol. Metab. 2020, 318, E600–E612. [CrossRef] [PubMed]
29. Álvarez, D.; Ceballo, K.; Olguín, S.; Martinez-Pinto, J.; Maliqueo, M.; Fernandois, D.; Sotomayor-Zárate, R.; Cruz, G. Prenatal
metformin treatment improves ovarian function in offspring of obese rats. J. Endocrinol. 2018, 239, 325–338. [CrossRef]
30. Armitage, J.A.; Khan, I.Y.; Taylor, P.D.; Nathanielsz, P.W.; Poston, L. Developmental programming of the metabolic syndrome
by maternal nutritional imbalance: How strong is the evidence from experimental models in mammals? J. Physiol. 2004, 561,
355–377. [CrossRef]
31. Stumvoll, M.; Nurjhan, N.; Perriello, G.; Dailey, G.; Gerich, J.E. Metabolic Effects of Metformin in Non-Insulin-Dependent
Diabetes Mellitus. N. Engl. J. Med. 1995, 333, 550–554. [CrossRef]
32. Butalia, S.; Gutierrez, L.; Lodha, A.; Aitken, E.; Zakariasen, A.; Donovan, L. Short- and long-term outcomes of metformin
compared with insulin alone in pregnancy: A systematic review and meta-analysis. Diabet. Med. 2017, 34, 27–36. [CrossRef]
33. Løvvik, T.S.; Carlsen, S.M.; Salvesen, Ø.; Steffensen, B.; Bixo, M.; Gómez-Real, F.; Lønnebotn, M.; Hestvold, K.V.; Zabielska, R.;
Hirschberg, A.L.; et al. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): A randomised,
double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019, 7, 256–266. [CrossRef]
34. Barbour, L.A.; Scifres, C.; Valent, A.M.; Friedman, J.E.; Buchanan, T.A.; Coustan, D.; Aagaard, K.; Thornburg, K.L.; Catalano, P.M.;
Galan, H.L.; et al. A cautionary response to SMFM statement: Pharmacological treatment of gestational diabetes. Am. J. Obstet.
Gynecol. 2018, 219, 367.e1–367.e7. [CrossRef]
35. Rajasingam, D.; Seed, P.T.; Briley, A.L.; Shennan, A.H.; Poston, L. A prospective study of pregnancy outcome and biomarkers of
oxidative stress in nulliparous obese women. Am. J. Obstet. Gynecol. 2009, 200, 395.e1–395.e9. [CrossRef] [PubMed]
36. Loche, E.; Blackmore, H.L.; Carpenter, A.A.; Beeson, J.H.; Pinnock, A.; Ashmore, T.J.; Aiken, C.E.; de Almeida-Faria, J.; Schoone-
jans, J.M.; Giussani, D.A.; et al. Maternal diet-induced obesity programmes cardiac dysfunction in male mice independently of
post-weaning diet. Cardiovasc. Res. 2018, 114, 1372–1384. [CrossRef] [PubMed]
37. De Barros Mucci, D.; Kusinski, L.C.; Wilsmore, P.; Loche, E.; Pantaleão, L.C.; Ashmore, T.J.; Blackmore, H.L.; Fernandez-Twinn,
D.S.; do Carmo, M.D.G.T.; Ozanne, S.E. Impact of maternal obesity on placental transcriptome and morphology associated with
fetal growth restriction in mice. Int. J. Obes. 2020, 44, 1087–1096. [CrossRef]
38. Ravelli, A.C.J.; Van Der Meulen, J.H.P.; Michels, R.P.J.; Osmond, C.; Barker, D.J.P.; Hales, C.N.; Bleker, O.P. Glucose tolerance in
adults after prenatal exposure to famine. Lancet 1998, 351, 173–177. [CrossRef]
39. Ravelli, A.C.J.; Van Der Meulen, J.H.P.; Osmond, C.; Barker, D.J.P.; Bleker, O.P. Obesity at the age of 50 y in men and women
exposed to famine prenatally. Am. J. Clin. Nutr. 1999, 70, 811–816. [CrossRef]
40. Roseboom, T.J.; Van der Meulen, J.H.P.; Osmond, C.; Barker, D.J.P.; Ravelli, A.C.J.; Schroeder-Tanka, J.M.; van Montfrans, G.A.;
Michels, R.P.J.; Bleker, O.P. Coronary heart disease after prenatal exposure to the Dutch famine, 1944–45. Heart 2000, 84, 595–598.
[CrossRef]
41. Roseboom, T.J.; Van der Meulen, J.H.P.; Osmond, C.; Barker, D.J.P.; Ravelli, A.C.J.; Bleker, O.P. Plasma lipid profiles in adults after
prenatal exposure to the Dutch famine. Am. J. Clin. Nutr. 2000, 72, 1101–1106. [CrossRef]
42. Berends, L.M.; Fernandez-Twinn, D.S.; Martin-Gronert, M.S.; Cripps, R.L.; Ozanne, S.E. Catch-up growth following intra-uterine
growth-restriction programmes an insulin-resistant phenotype in adipose tissue. Int. J. Obes. 2013, 37, 1051–1057. [CrossRef]
43. Berends, L.M.; Dearden, L.; Tung, Y.C.L.; Voshol, P.; Fernandez-Twinn, D.S.; Ozanne, S.E. Programming of central and peripheral
insulin resistance by low birthweight and postnatal catch-up growth in male mice. Diabetologia 2018, 61, 2225–2234. [CrossRef]
[PubMed]
44. Cinti, S.; Mitchell, G.; Barbatelli, G.; Murano, I.; Ceresi, E.; Faloia, E.; Greenberg, A.S.; Obin, M.S. Adipocyte death defines
macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 2005, 46, 2347–2355. [CrossRef]
[PubMed]
45. Strissel, K.J.; Stancheva, Z.; Miyoshi, H.; Perfield, J.W.; DeFuria, J.; Jick, Z.; Greenberg, A.S.; Obin, M.S. Adipocyte death, adipose
tissue remodeling, and obesity complications. Diabetes 2007, 56, 2910–2918. [CrossRef]
46. Xu, H.; Barnes, G.T.; Yang, Q.; Tan, G.; Yang, D.; Chou, C.J.; Sole, J.; Nichols, A.; Ross, J.S.; Tartaglia, L.A.; et al. Chronic
inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 2003, 112,
1821–1830. [CrossRef]
47. Varghese, M.; Griffin, C.; McKernan, K.; Eter, L.; Lanzetta, N.; Agarwal, D.; Abrishami, S.; Singer, K. Sex differences in
inflammatory responses to adipose tissue lipolysis in diet-induced obesity. Endocrinology 2019, 160, 293–312. [CrossRef]
48. Yokomizo, H.; Inoguchi, T.; Sonoda, N.; Sakaki, Y.; Maeda, Y.; Inoue, T.; Hirata, E.; Takei, R.; Ikeda, N.; Fujii, M.; et al. Maternal
high-fat diet induces insulin resistance and deterioration of pancreatic β-cell function in adult offspring with sex differences in
mice. Am. J. Physiol. Endocrinol. Metab. 2014, 306, E1163–E1175. [CrossRef]
49. Aiken, C.E.; Ozanne, S.E. Sex differences in developmental programming models. Reproduction 2013, 145, 145–146. [CrossRef]
50. Dearden, L.; Bouret, S.G.; Ozanne, S.E. Sex and gender differences in developmental programming of metabolism. Mol. Metab.
2018, 15, 8–19. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 8104 14 of 14
51. Tarry-Adkins, J.L.; Aiken, C.E.; Ozanne, S.E. Neonatal, infant, and childhood growth following metformin versus insulin
treatment for gestational diabetes: A systematic review and meta-analysis. PLoS Med. 2019, 16, e1002848. [CrossRef] [PubMed]
52. Rowan, J.A.; Rush, E.C.; Obolonkin, V.; Battin, M.; Wouldes, T.; Hague, W.M. Metformin in gestational diabetes: The offspring
follow-up (MiG TOFU)—Body composition at 2 years of age. Diabetes Care 2011, 34, 2279–2284. [CrossRef] [PubMed]
53. Chiswick, C.A.; Reynolds, R.M.; Denison, F.C.; Drake, A.J.; Forbes, S.; Newby, D.E.; Walker, B.R.; Quenby, S.; Wray, S.;
Weeks, A.; et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): A randomised,
double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015, 3, 778–786. [CrossRef]
